Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.75 |
| ▸ | EGFR | P00533 | 16/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 13/20 | 0.75 |
| ▸ | FLT1 | P17948 | 13/20 | 0.75 |
| ▸ | FLT4 | P35916 | 13/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.63 |
| ▸ | TEK | Q02763 | 2/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.63 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.63 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | KIF5B | P33176 | 2/20 | 0.63 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.63 |
| ▸ | PLK4 | O00444 | 1/20 | 0.63 |
| ▸ | CIT | O14578 | 1/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.63 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.63 |
| ▸ | STK10 | O94804 | 1/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614506 | 0.93 | KDR (0.75) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL17179598 | 0.88 | KDR (0.65) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL1781194 | 0.88 | KDR (0.67) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL2136770 | 0.86 | EGFR (1.00) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL3131165 | 0.85 | EGFR (0.75) | KDREGFREPHA2EPHB4RET | |
| SCHEMBL2136853 | 0.85 | KDR (0.74) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL2136783 | 0.85 | EGFR (0.74) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL13617552 | 0.84 | KDR (0.75) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL3152430 | 0.82 | KDR (0.80) | KDREGFRFGFR1FLT1FLT4 | |
| SCHEMBL13163378 | 0.82 | KDR (0.75) | KDREGFRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2021-09-09 | — | — | US | disclosed |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2020-08-20 | — | — | US | disclosed |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | GENZYME CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180118716-A1 | Chemical Process | GENZYME CORPORATION (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-9815816-B2 | Chemical process for the synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | GENZYME CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160185754-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | ASTRAZENECA AB (SE) | 2016-06-30 | — | — | US | disclosed |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-9040548-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-8642608-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2014-02-04 | — | — | US | disclosed |
| US-8163926-B2 | Process for the synthesis of piperidinyl sulphonate esters | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-20120095229-A1 | CHEMICAL PROCESS | GENZYME CORPORATION | 2012-04-19 | — | — | US | disclosed |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
| US-20090203905-A1 | CHEMICAL PROCESS | GENZYME CORPORATION | 2009-08-13 | — | — | US | disclosed |
| EP-1676845-B1 | New quinazoline derivatives | ASTRAZENECA AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB | 2007-11-15 | — | — | US | disclosed |
| US-7173038-B1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| EP-1676845-A1 | New quinazoline derivatives | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1244647-B1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | KDR 3/4885EGFR 199/4885FGFR1 161/4885 |
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 207/4885FGFR1 154/4885 |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | FLT1, FLT4, KDR | KDR 3/4885EGFR 183/4885FGFR1 143/4885 |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 179/4885FGFR1 196/4885 |
| US-20090203905-A1 | CHEMICAL PROCESS | CYP3A4, CYP3A5, CYP3A7 | KDR 3543/4885EGFR 3879/4885FGFR1 2764/4885 |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 183/4885FGFR1 143/4885 |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 181/4885FGFR1 135/4885 |
| US-20160185754-A1 | Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline | CYP3A4, CYP3A7, CYP4B1 | KDR 3217/4885EGFR 3838/4885FGFR1 2445/4885 |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 181/4885FGFR1 135/4885 |
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 179/4885FGFR1 196/4885 |
| US-20120095229-A1 | CHEMICAL PROCESS | CYP3A4, CYP3A5, CYP3A7 | KDR 3543/4885EGFR 3879/4885FGFR1 2764/4885 |
| US-20180118716-A1 | Chemical Process | CYP3A4, CYP3A5, CYP3A7 | KDR 3543/4885EGFR 3879/4885FGFR1 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.